Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sanford-Burnham to Partner with Pfizer

Published: Tuesday, August 20, 2013
Last Updated: Tuesday, August 20, 2013
Bookmark and Share
The collaboration will see the organisations identify new therapeutic targets for preventing and treating complications of obesity and diabetes.

The team will utilize novel screening tools including systems-biology approaches and technologies developed at the Institute with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes. 

Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. The collaboration combines our expertise in fundamental disease biology and muscle metabolism with Pfizer’s expertise in drug discovery. Investigators will utilize the Conrad Prebys Center for Chemical Genomics to screen for new relevant targets using investigational compounds from Pfizer as well as evaluate compounds previously identified from the NIH chemical library. Once the screening identifies compounds of interest, Sanford-Burnham and Pfizer scientists will collaborate to characterize and further study the “hit” compounds to understand their mechanism of action. These compounds will then be used as “probes” to identify novel therapeutic targets for the treatment of diabetes. 

Finding new medicines for diabetes 
“Diabetes presents an enormous public health burden. There is an acute need to translate innovative science into potential new medicines for people living with this debilitating disease,” said Tim Rolph, Vice President and Head of Cardiovascular and Metabolic Diseases Research Unit at Pfizer. “Pfizer’s collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes.” Pfizer will have access to Sanford-Burnham’s team of world-class scientists and translational infrastructure dedicated to finding new approaches to targeting disease. Collaborating with researchers at a major pharmaceutical company will help us achieve our mission of translating high-impact science into new therapies. “This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem – complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research,” said Stephen Gardell, Ph.D., senior director of scientific resources in our Diabetes and Obesity Research Center. 

Advancing drug discovery in the Prebys Center
The Prebys Center houses Sanford-Burnham’s state-of-the-art screening facility established to accelerate the rate of commercialization of basic research in an independent medical research setting. Our discovery capabilities include: ultra-high throughput screening, high-content screening, phenotypic screening, and target-deconvolution technologies. The Prebys Center is led and staffed by industry-trained professionals who work closely with Sanford-Burnham investigators and industry collaborators to translate scientific findings into actionable drug discovery projects.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New ACE-inhibiting Molecule Found in the Asparagus
Scientists have determined that sulfur-containing compounds in plants can inhibit ACE.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Shedding Light On Century-Old Biochemical Mystery
Yale scientists have used magnetic resonance measurements to show how glucose is metabolized in yeast to answer the puzzle of the “Warburg Effect.”
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Metabolon and BCM Show Metabolomics May Play Key Role in Precision Medicine
Metabolon’s technology enhances understanding of genetic data and improves health assessment in newly published study.
Newly Discovered Cells Restore Liver Damage in Mice Without Cancer Risk
The liver is unique among organs in its ability to regenerate after being damaged. Exactly how it repairs itself remained a mystery until recently, when researchers supported by the NIH discovered a type of cell in mice essential to the process
Study Finds Cutting Dietary Fat Reduces Body Fat More than Cutting Carbs
In a recent study, restricting dietary fat led to body fat loss at a rate 68 percent higher than cutting the same number of carbohydrate calories when adults with obesity ate strictly controlled diets.
Inappropriate Medical Food Use in Managing Patients with a Type of Metabolic Disorder
Researchers have proposed that there is a need for more rigorous clinical study of dietary management practices for patients with IEMs, including any associated long-term side effects, which may in turn result in the need to reformulate some medical foods.
Medical Researchers a Step Closer to Developing Anti-Obesity Pill
A weight loss pill could soon be possible thanks to the work of Deakin University medical researchers.
Engineered Bacterium Produces Important Industrial Chemical
A Korean research team has reported the production of 1,3-diaminopropane via fermentation of an engineered bacterium.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!